The Pressing Need for Early Detection of Mucormycosis during COVID-19
AsiaNet 90204
DONGGUAN, China, June 21, 2021 /PRNewswire=KYODO JBN/ --
Mucormycosis or black fungus, a devastating infection that soars in India
during COVID-19 has seized global attention. Recently, the country's
mucormycosis cases reached over 57,150 and resulted in 54% mortality (
). Apart from the association with high diabetes prevalence in India, COVID-19
infected countries (Pakistan, Russia, Nepal(
), Chile(
), Brazil, etc.) have also described the same issue, areas with high diabetes
and COVID-19 infection rates should be alarmed.
Unfortunately, mucormycosis is always being diagnosed late with prolonged
COVID-19 healthcare burdens that deteriorate the situation. As a company making
continuous research and contribution to the world's major infectious diseases
with the mission to Enable Disease Identification Earlier, More Accurate,
Convenient and Affordable, Fapon Biotech Inc.(
http://en.faponbiotech.com/index.html ) (Fapon Biotech) calls for cooperation
with academic and industry partners in developing mucormycosis diagnostic tests
to ease the challenge by sharing the abilities of upstream raw material
development platforms and downstream reagent application platforms.
Fapon Biotech is one of the mainstream COVID-19 reagent raw material suppliers
with proven experiences helping partners to launch accredited COVID-19 reagents
in a short time. The company has over 1000 IVD partners worldwide with more
than 10 years of business operation in India. Its technology platforms can
match the R&D process from partners easily and provide supports from biomarker
discovery to commercialization. Through different application platforms of
Fapon Biotech (Colloidal Gold/Immunofluorescence/ELISA/CLIA/Latex-Enhanced
Immunoturbidimetry/PCR/etc.), biomarkers can quickly complete the process of
application development. For partners encountering production challenges, OEM
and contract manufacturing services with the capacity reaching hundreds of
grams of each batch are available. Because of a strong relationship with
laboratories and IVD manufacturers in India, cooperating with Fapon Biotech
will have the access to more resources and commercial opportunities, such as
clinical samples for research and product validation, technology iterations,
product launch and promotion, etc.
As the virus continues its mutation and triggers diseases like mucormycosis to
complicate the situation, rapid responses via global cooperation will be
crucial for areas with overwhelmed healthcare burdens. Fapon Biotech is
committed to fueling the advancement of COVID-19 diagnosis through
collaborations with international IVD partners.
About Fapon Biotech
Fapon Biotech was founded in 2001. Guided by the mission of "Enable Disease
Identification Earlier, More Accurate, Convenient and Affordable," the company
focuses on the future needs of biotechnology developments and provides global
diagnostic companies with high-performance IVD reagent raw materials, such as
antigens, antibodies, and enzymes, as well as one-stop solutions with
instrument and reagent services.
SOURCE: Fapon Biotech Inc.
Image Attachments Links:
Link: http://asianetnews.net/view-attachment?attach-id=394248
Caption: Fapon Biotech calls for cooperation with academic and industry partners in
developing mucormycosis diagnostic tests to ease the challenge by sharing the
abilities of upstream raw material development platforms and downstream reagent
application platforms.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。